Mallinckrodt (MNK) Tops Q4 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts MNK Hot Sheet
Join SI Premium – FREE
Mallinckrodt (NYSE: MNK) reported Q4 EPS of $2.40, $0.35 better than the analyst estimate of $2.05. Revenue for the quarter came in at $804.9 million versus the consensus estimate of $772.52 million.
- As separately announced today, reached an agreement in principle for a global settlement with a broad-based group of plaintiffs that would resolve all opioid-related claims against the company and its subsidiaries, and taking actions to address near-term maturities to strengthen capital structure
For earnings history and earnings-related data on Mallinckrodt (MNK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Myriad Genetics (MYGN) Tops Q3 EPS by 9c ; Offers Guidance
- Viemed Healthcare, Inc. (VMD) Misses Q3 EPS by 2c; updates guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
